CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-20). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 836 · Search date 2026-07-20 · Methodology v0.6

HongJam steamed mature silkworm hydrolysate or powder,
does it really help with Improved memory and global cognition in patients with mild cognitive impairment?

30-Second Summary
D
Evidence Grade D · 28 · Safety unknown
A delayed-memory signal exists, but global cognitive improvement and a silkworm-only effect remain unconfirmed
What the
research shows
HongJam hydrolysate or mature silkworm alone receives D with 28 points for mild cognitive impairment. The published 62-person, 12-week trial did not test HongJam hydrolysate alone; it coadministered a 2.5-g mature silkworm pill with a commercial oral nutritional supplement. Delayed memory improved, but the primary K-RBANS total score and other cognitive domains were nonsignificant, and the effect cannot be assigned to either component. Hydrolysate evidence is centered on preclinical mouse work, and the trademarked individually recognized ingredient lacks independent human replication as a stand-alone intervention.
What the
ads claim
Marketing can combine animal memory behavior, one delayed-memory score, and regulatory recognition into global cognitive improvement or dementia prevention. The published evidence best fits a short, small trial of one combined product and does not show slower dementia progression or restored daily function.
*

Useful facts when choosing a product

  • HongJam is made by steaming mature silkworms and then drying and milling them, whereas an enzyme hydrolysate is a separately specified ingredient with altered composition and absorption characteristics.
  • Korean individual recognition applies only to the specified ingredient, manufacturing standard, and conditions of use and does not automatically extend to generic silkworm powders or other processes.
  • The positive published human result came from mature silkworm pills given together with an oral nutritional supplement and therefore must not be interpreted as a silkworm-only effect.
  • Silkworm or insect-protein allergy and controls for identity, microbes, heavy metals, and other quality variables matter, and the product must not replace diagnosis or standard management of cognitive decline.
Gap Measurement · Verdict 836 · D 28
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Kim and colleagues in 2025 randomized 62 adults with mild cognitive impairment for 12 weeks to a 2.5-g mature silkworm pill plus a commercial oral nutritional supplement or placebo pills plus an isocaloric placebo supplement. Delayed-memory change favored intervention at p=0.018, but the primary K-RBANS total score and immediate-memory, visuospatial, language, and attention domains were nonsignificant. The study did not evaluate the trademarked individually recognized ingredient alone, and company research employees were coauthors. A separate hydrolysate study assessed memory behavior and molecular markers in 96 mice and does not establish human memory or clinical-function benefit.

02

Why this is classified as D (28)

The 62-person trial combined a 2.5-g mature silkworm pill with a commercial nutritional supplement, so its delayed-memory signal cannot be attributed to HongJam alone, and the primary K-RBANS total score was null. Hydrolysate evidence is preclinical, with no independent stand-alone replication of the trademarked individually recognized ingredient. Combined-product and animal evidence without stand-alone confirmation supports D with 28 points. Safety remains unchanged and separate.

Counterpoint. Exercise, hearing and sleep care, vascular-risk control, and accurate etiologic evaluation remain priorities; HongJam, if used, is an adjunctive choice.

Rejudgment record. Reassessment (cross-check reflected) — Recognized that the 62-person trial combined a 2.5-g mature silkworm pill with a commercial nutritional supplement, precluding stand-alone attribution, and applied the null primary K-RBANS total score, preclinical hydrolysate evidence, and absence of independent stand-alone replication of the trademarked individually recognized ingredient

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Stand-alone memory and cognitive benefit of HongJam hydrolysate or mature silkwormDThe human trial combined a 2.5-g mature silkworm pill with a commercial nutritional supplement, while hydrolysate evidence is preclinical, so stand-alone efficacy is unconfirmed.
Delayed-memory benefit of mature silkworm pills plus a nutritional supplementCA delayed-memory signal appeared in 62 participants, but the primary total and other domains were null and the contributing component cannot be identified.
Prevention, treatment, or slowed progression of dementia?No HongJam human trial evaluating dementia incidence, progression, or daily function was identified.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Kim MJ et al. 2025Twelve-week randomized blinded placebo-controlled combined-intervention trial32Maeil Health Nutrition product and research involvement; two company employees were coauthorsPrimary K-RBANS total score and domain scores including delayed memoryA combined intervention of a 2.5-g mature silkworm pill plus a commercial oral nutritional supplement improved delayed-memory change, but total and other domain scores were nonsignificant and the result cannot be attributed to HongJam alone.Limited human combined-product signal without stand-alone attribution
Kim YH et al. 2025Randomized and blinded preclinical mouse model of mild cognitive impairment16Korean public agricultural research support; one food-company employee was a coauthorMemory behavior, CREB-BDNF signaling, and brain mitochondrial functionHongJam and its enzyme hydrolysate improved selected memory behaviors and molecular measures, but this was not a human clinical trial.Mechanistic support, not clinical efficacy
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-20).

Kim MJ, Lee SM, Sun K, et al. Effects of oral nutritional supplements plus mature silkworm pill on cognitive function in Korean adults with mild cognitive impairment: a 12-week randomized blinded clinical trial. Front Nutr. 2025;12:1605525. PMID: 41229538. PMCID: PMC12604101. DOI: 10.3389/fnut.2025.1605525.
checked
Kim YH, Phuong N, Hoang NMA, Kim HJ, Baik MY, Koh YH. Silkworm Enzyme Hydrolysates Improve Memory in MCI Models via CREB-BDNF Signaling and Enhanced Brain Mitochondrial Function. Nutrients. 2025;17(12):2044. PMID: 40573155. PMCID: PMC12196421. DOI: 10.3390/nu17122044.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none

Cite this verdict

HongJam steamed mature silkworm hydrolysate or powder x memory and cognition in mild cognitive impairment Evidence Grade D card
[Chamgap] HongJam steamed mature silkworm hydrolysate or powder x memory and cognition in mild cognitive impairment — Evidence Grade D·28. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/hongjam-steamed-mature-silkworm-mci-memory-cognition/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.